Cargando…
NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients
BACKGROUND: The presence of disseminated tumor cells (DTCs) in bone marrow (BM) is an independent prognostic factor in early breast cancer but does not uniformly predict outcome. Tumor cells can persist in a quiescent state over time, but clinical studies of markers predicting the awakening potentia...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190561/ https://www.ncbi.nlm.nih.gov/pubmed/30322396 http://dx.doi.org/10.1186/s13058-018-1049-0 |
_version_ | 1783363598422114304 |
---|---|
author | Borgen, Elin Rypdal, Maria C. Sosa, Maria Soledad Renolen, Anne Schlichting, Ellen Lønning, Per E. Synnestvedt, Marit Aguirre-Ghiso, Julio A. Naume, Bjørn |
author_facet | Borgen, Elin Rypdal, Maria C. Sosa, Maria Soledad Renolen, Anne Schlichting, Ellen Lønning, Per E. Synnestvedt, Marit Aguirre-Ghiso, Julio A. Naume, Bjørn |
author_sort | Borgen, Elin |
collection | PubMed |
description | BACKGROUND: The presence of disseminated tumor cells (DTCs) in bone marrow (BM) is an independent prognostic factor in early breast cancer but does not uniformly predict outcome. Tumor cells can persist in a quiescent state over time, but clinical studies of markers predicting the awakening potential of DTCs are lacking. Recently, experiments have shown that NR2F1 (COUP-TF1) plays a key role in dormancy signaling. METHODS: We analyzed the NR2F1 expression in DTCs by double immunofluorescence (DIF) staining of extra cytospins prepared from 114 BM samples from 86 selected DTC-positive breast cancer patients. Samples collected at two or more time points were available for 24 patients. Fifteen samples were also analyzed for the proliferation marker Ki67. RESULTS: Of the patients with detectable DTCs by DIF, 27% had ≥ 50% NR2F1(high) DTCs, chosen a priori as the cut-off for “dormant profile” classification. All patients with systemic relapse within 12 months after BM aspiration carried ≤ 1% NR2F1(high) DTCs, including patients who transitioned from having NR2F1(high)-expressing DTCs in previous BM samples. Of the patients with serial samples, half of those with no relapse at follow-up had ≥ 50% NR2F1(high) DTCs in the last BM aspiration analyzed. Among the 18 relapse-free patients at the time of the last DTC-positive BM aspiration with no subsequent BM analysis performed, distant disease-free intervals were favorable for patients carrying ≥ 50% NR2F1(high) DTCs compared with those with predominantly NR2F1(low) DTCs (p = 0.007, log-rank). No survival difference was observed by classification according to Ki67-expressing DTCs (p = 0.520). CONCLUSIONS: Our study translates findings from basic biological analysis of DTC dormancy to the clinical situation and supports further clinical studies of NR2F1 as a marker of dormancy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13058-018-1049-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6190561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-61905612018-10-23 NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients Borgen, Elin Rypdal, Maria C. Sosa, Maria Soledad Renolen, Anne Schlichting, Ellen Lønning, Per E. Synnestvedt, Marit Aguirre-Ghiso, Julio A. Naume, Bjørn Breast Cancer Res Short Report BACKGROUND: The presence of disseminated tumor cells (DTCs) in bone marrow (BM) is an independent prognostic factor in early breast cancer but does not uniformly predict outcome. Tumor cells can persist in a quiescent state over time, but clinical studies of markers predicting the awakening potential of DTCs are lacking. Recently, experiments have shown that NR2F1 (COUP-TF1) plays a key role in dormancy signaling. METHODS: We analyzed the NR2F1 expression in DTCs by double immunofluorescence (DIF) staining of extra cytospins prepared from 114 BM samples from 86 selected DTC-positive breast cancer patients. Samples collected at two or more time points were available for 24 patients. Fifteen samples were also analyzed for the proliferation marker Ki67. RESULTS: Of the patients with detectable DTCs by DIF, 27% had ≥ 50% NR2F1(high) DTCs, chosen a priori as the cut-off for “dormant profile” classification. All patients with systemic relapse within 12 months after BM aspiration carried ≤ 1% NR2F1(high) DTCs, including patients who transitioned from having NR2F1(high)-expressing DTCs in previous BM samples. Of the patients with serial samples, half of those with no relapse at follow-up had ≥ 50% NR2F1(high) DTCs in the last BM aspiration analyzed. Among the 18 relapse-free patients at the time of the last DTC-positive BM aspiration with no subsequent BM analysis performed, distant disease-free intervals were favorable for patients carrying ≥ 50% NR2F1(high) DTCs compared with those with predominantly NR2F1(low) DTCs (p = 0.007, log-rank). No survival difference was observed by classification according to Ki67-expressing DTCs (p = 0.520). CONCLUSIONS: Our study translates findings from basic biological analysis of DTC dormancy to the clinical situation and supports further clinical studies of NR2F1 as a marker of dormancy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13058-018-1049-0) contains supplementary material, which is available to authorized users. BioMed Central 2018-10-16 2018 /pmc/articles/PMC6190561/ /pubmed/30322396 http://dx.doi.org/10.1186/s13058-018-1049-0 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Short Report Borgen, Elin Rypdal, Maria C. Sosa, Maria Soledad Renolen, Anne Schlichting, Ellen Lønning, Per E. Synnestvedt, Marit Aguirre-Ghiso, Julio A. Naume, Bjørn NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients |
title | NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients |
title_full | NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients |
title_fullStr | NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients |
title_full_unstemmed | NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients |
title_short | NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients |
title_sort | nr2f1 stratifies dormant disseminated tumor cells in breast cancer patients |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190561/ https://www.ncbi.nlm.nih.gov/pubmed/30322396 http://dx.doi.org/10.1186/s13058-018-1049-0 |
work_keys_str_mv | AT borgenelin nr2f1stratifiesdormantdisseminatedtumorcellsinbreastcancerpatients AT rypdalmariac nr2f1stratifiesdormantdisseminatedtumorcellsinbreastcancerpatients AT sosamariasoledad nr2f1stratifiesdormantdisseminatedtumorcellsinbreastcancerpatients AT renolenanne nr2f1stratifiesdormantdisseminatedtumorcellsinbreastcancerpatients AT schlichtingellen nr2f1stratifiesdormantdisseminatedtumorcellsinbreastcancerpatients AT lønningpere nr2f1stratifiesdormantdisseminatedtumorcellsinbreastcancerpatients AT synnestvedtmarit nr2f1stratifiesdormantdisseminatedtumorcellsinbreastcancerpatients AT aguirreghisojulioa nr2f1stratifiesdormantdisseminatedtumorcellsinbreastcancerpatients AT naumebjørn nr2f1stratifiesdormantdisseminatedtumorcellsinbreastcancerpatients |